Kun Deng^1,2,3, Jianliang Huang^1,2,3, Danyang Li^2,3, Wei Gao^2,3, Minghua Wu^2,3,4,*, Mingsheng Lei^1,5,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069442 - 30 December 2025

Abstract Background: Glioblastoma (GBM) prognosis has seen little improvement over the past two decades. While immunotherapy has revolutionized cancer treatment, its impact on GBM remains limited. To characterize the evolving research landscape and identify future directions in GBM immunotherapy, we conducted a comprehensive bibliometric review. Methods: All literature related to immunotherapy in GBM from 1999 to 2024 was collected from the Web of Science Core Collection. CtieSpace and VOSviewer were used to conduct bibliometric analysis and visualize the data. Results: Bibliometric analysis identified 5038 publications authored by 23,335 researchers from 4699 institutions across 96 countries/regions, published in… More >

Jianan Lei^*, Zhuona Ni, Ruidi Zhang

Oncology Research, Vol.33, No.11, pp. 3347-3373, 2025, DOI:10.32604/or.2025.067445 - 22 October 2025

Abstract This review aims to explore the development, challenges, and future directions of UCAR cell therapy as a scalable alternative to autologous CAR-T for cancer treatment. Consequently, limitations of autologous CAR-T, including long production, variable quality, and cost, drive off-the-shelf UCAR development to standardize manufacturing and improve access. Current UCAR-T cell strategies focus on mitigating the risks of graft-vs.-host disease and host-vs.-graft rejection through advanced gene editing technologies, including clustered regularly interspaced short palindromic repeat-associated system Cas9-mediated knockout of the T cell receptor, human leukocyte antigen, and cluster of differentiation 52 (CD52). Beyond conventional T cells, cell… More >

Tian-Tian Li^1,2,3,#, Ming-Yao Meng^1,2,4,#, Zheng Yu⁵, Yang-Fan Guo^1,2,4, Yi-Yi Zhao^1,2,4, Hui Gao^1,2,4, Li-Li Yang^1,2,3, Li-Rong Yang^1,2,3, Meng-Yuan Chu^1,2,3, Shan He^1,2,4, Yuan Liu^1,2,4, Xiao-Dan Wang^1,2,4, Wen-Ju Wang^1,2,4, Zong-Liu Hou^1,2,4, Li-Wei Liao^1,2,4,*, Lin Li^1,2,4,*

Oncology Research, Vol.33, No.11, pp. 3447-3467, 2025, DOI:10.32604/or.2025.065394 - 22 October 2025

Abstract Background: Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated significant clinical efficacy in hematological malignancies. However, their application to solid tumors remains substantially limited by multiple challenges, including the risk of off-target effects. Hence, optimizing CAR-T cells for stronger antigen binding is essential. Methods: In this study, we employed a classical anti-human endothelial growth factor receptor 2 (HER2) single-chain variable fragment (scFv) derived from trastuzumab, alongside an anti-HER2-13 scFv identified from a combinatorial cellular CAR library, for the construction of a third-generation CAR-T cell. Meanwhile, the phenotypes and both in vitro and in vivo functions of… More > Graphic Abstract

ZHENGYI WANG^1,*, LIANG ZHOU¹, XIAOYING WU²

Oncology Research, Vol.32, No.9, pp. 1479-1516, 2024, DOI:10.32604/or.2024.048564 - 23 August 2024

Abstract Chimeric antigen receptor T-cesll therapy (CAR–T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment. However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR–T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR–T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy. These factors have significantly impeded the widespread More > Graphic Abstract

HANYANG GUAN^1,#, YUE WU^2,#, LU LI^3,#, YABING YANG¹, SHENGHUI QIU¹, ZHAN ZHAO¹, XIAODONG CHU¹, JIASHUAI HE¹, ZUYANG CHEN¹, YIRAN ZHANG¹, HUI DING¹, JINGHUA PAN^1,*, YUNLONG PAN^1,*

Oncology Research, Vol.31, No.4, pp. 437-448, 2023, DOI:10.32604/or.2023.029924 - 25 June 2023

Abstract Neoantigen-targeted immunotherapy is a rapidly advancing field that holds great promise for treating cancer. The recognition of antigens by immune cells is a crucial step in tumor-specific killing, and neoantigens generated by mutations in cancer cells possess high immunogenicity and are selectively expressed in tumor cells, making them an attractive therapeutic target. Currently, neoantigens find utility in various domains, primarily in the realm of neoantigen vaccines such as DC vaccines, nucleic acid vaccines, and synthetic long peptide vaccines. Additionally, they hold promise in adoptive cell therapy, encompassing tumor-infiltrating cells, T cell receptors, and chimeric antigen More > Graphic Abstract

ZHIXIONG WANG^1,2, NA RISU², JIAYU FU², HUI LIU³, GUOMIN ZHOU³, QIAN LIU³, YAN ZOU⁴, JIAXING TANG⁴, LONG LI⁴, XUEKAI ZHU^4,*

BIOCELL, Vol.45, No.1, pp. 157-165, 2021, DOI:10.32604/biocell.2021.010261 - 26 January 2021

Abstract Chimeric antigen receptor (CAR) T-cell therapy is mostly limited to hematological malignancies and has a poor effect on solid tumors. CAR T cells as a kind of immune cell may be affected by some immunomodulatory drugs such as pomalidomide, so the use of pomalidomide may improve the effect of CAR T cells on solid tumors. In this study, CD133- or HER2-specific CAR T cells were chosen to investigate whether pomalidomide can regulate the function of CAR T cells in vitro. We found that pomalidomide can significantly enhance the ability of CD133-CAR T cells and HER2-CAR T More >